Goldman’s playbook for 5% 10-year yield. These strong balance sheet stocks are winners
“We expect investors will continue to focus on balance sheet strength and avoid companies that are most vulnerable to increased borrow costs,” the firm said.
Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond. A look at the numbers
Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative. Here’s why.
Tesla discloses DOJ probes over vehicle range, personal benefits and more
Tesla’s Q3 10-Q had some new information about the status of legal actions against the company.
Apple, caught by surprise in generative AI boom, to spend $1 billion per year to catch up: Report
Apple is focused on developing its own AI products to catch up to its competitors.
‘Marvel’s Spider-Man 2′ video game breaks PlayStation Studios’ 24-hour sales record
Customers bought more than 2.5 million copies of “Marvel’s Spider-Man 2” in its first 24 hours.
Argentine assets under pressure as Economy Minister Massa beats far-right Milei in first-round vote
Uncertainty ahead of the run-off presidential vote next month “will likely keep Argentine assets under pressure,” strategists at ING said.
Bill Ackman covers bet against Treasurys, says ‘too much risk in the world’ to bet against bonds
The billionaire hedge fund manager first disclosed his bearish position on 30-year Treasurys in August.
Tsingtao responds to viral video showing a Chinese beer worker urinating into a tank
Tsingtao Brewery said Monday that an investigation was currently underway after a viral video surfaced showing a staff member urinating into one of its tanks.
How Micron is building the biggest chip fab in U.S. history despite a China ban and smartphone slump
Micron is the only company making memory in the U.S. That’s made it a target in the chip war with China, but it’s still building the country’s biggest chip fab.
‘The bond vigilante is coming back,’ UBS strategist says
The “bond vigilantes are coming back” as investors continue to sell amid the prospect of a growing fiscal deficit, according to UBS Asset Management’s Kevin Zhao.
